指南与共识呼吸衰竭与机械通气

马来西亚哮喘护理中短效β2受体激动剂过度依赖的国家专家共识

National expert consensus on short-acting beta2-agonist overreliance in asthma care in Malaysia.
指南 / 共识 · J Asthma · 2024-07-01
一句话结论马来西亚13名专家通过德尔菲法达成11条共识,旨在消除哮喘护理中短效β2受体激动剂的过度处方与过度依赖。

该国家专家共识通过检索PubMed数据库(截至2023年6月)中关于短效β2受体激动剂(SABA)过度使用负担及哮喘指南推荐的文章,并由13名马来西亚专家(5名呼吸科医生、4名家庭医学专家、2名急诊科医生、2名药师)采用德尔菲法制定共识推荐。最终形成11条共识声明,每条声明均达到至少70%的预先设定同意水平。声明反映了马来西亚哮喘护理中SABA过度依赖的现状,并提出了消除SABA过度处方和过度依赖的推荐。该共识文件预期将提高马来西亚医护人员的认识,并促进该国哮喘护理的持续改进。

要点

  • 共识由13名马来西亚专家(5名呼吸科医生、4名家庭医学专家、2名急诊科医生、2名药师)通过德尔菲法制定,共形成11条声明。
  • 每条共识声明均达到至少70%的预先设定同意水平。
  • 共识旨在提高对SABA过度使用的认识,并提供消除SABA过度处方和过度依赖的推荐。
  • 证据来源包括随机对照试验、系统评价、Meta分析、观察性研究、指南和调查,检索截至2023年6月。
  • 共识聚焦马来西亚背景下的SABA过度依赖负担及具体推荐。

适用人群与场景

  • 马来西亚哮喘护理中的医护人员及患者

研究设计与关键结果

  • 制定机构为马来西亚专家委员会,通过检索PubMed数据库(截至2023年6月)获取SABA过度使用负担及哮喘指南推荐的相关文献,并采用德尔菲法形成共识。
  • 专家委员会由13名医护人员组成:5名呼吸科医生、4名家庭医学专家、2名急诊科医生、2名药师。
  • 共形成11条共识声明,每条声明均达到至少70%的预先设定同意水平。
  • 声明反映了马来西亚哮喘护理中SABA过度依赖的现状,并提出了消除SABA过度处方和过度依赖的推荐。

证据类型、等级与局限

  • 证据类型:专家共识(德尔菲法)。
  • 文献检索纳入随机对照试验、系统评价、Meta分析、观察性研究、指南和调查,摘要为英文,发表截至2023年6月。
  • 相关推荐亦来源于经核实的医学组织与学会网站。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 该共识旨在提高马来西亚医护人员对SABA过度使用的认识,并促进该国哮喘护理的持续改进。

指南或共识出处

  • 指南名称:马来西亚哮喘护理中短效β2受体激动剂过度依赖的国家专家共识(National expert consensus on short-acting beta2-agonist overreliance in asthma care in Malaysia);发布机构:马来西亚专家委员会;年份:原文未写明

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Inappropriate use of short-acting beta2-agonists (SABA) in asthma has been associated with undesired outcomes. This national expert consensus was developed to increase awareness of SABA overuse and provide recommendations on the ways to eliminate SABA overprescription and overreliance in Malaysia.

DATA SOURCES: This expert consensus was developed by searching the PubMed database, using index terms to identify SABA overuse-related burden and recommendations made in asthma guidelines. Consensus recommendations were made via the Delphi method, involving a Malaysian expert committee comprising 13 healthcare professionals (five pulmonologists, four family medicine specialists, two emergency medicine physicians and two pharmacists).

STUDY SELECTIONS: The articles reviewed include randomized controlled trials, systematic reviews, meta-analyses, observational studies, guidelines, and surveys, with abstracts in English and published up until June 2023. Relevant recommendations were also sourced from verified websites of medical organizations and societies.

RESULTS: Eleven consensus statements were developed, each statement achieving a priori agreement level of at least 70%. The statements reflect SABA overreliance in asthma care, as well as recommendations to eliminate SABA overprescription and overreliance in Malaysia. Supporting evidence in the literature as well as expert committee discussions leading to the development of the finalized statements were elaborated.

CONCLUSION: This national expert consensus discussed the burden of SABA overreliance and made specific recommendations to eliminate SABA overprescription and overreliance in the Malaysian context. This consensus document is anticipated to impart better awareness among Malaysian healthcare providers and contribute to the continuous improvement of asthma care in the country.

来源:J Asthma,查看原文。版权归原作者所有。

参考来源

  1. Ban AY, Taher SW, Muneswarao J, et al. National expert consensus on short-acting beta2-agonist overreliance in asthma care in Malaysia. J Asthma. 2024. PMID: 38832793. doi:10.1080/02770903.2024.2361780

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。